Improving the Regulatory Review Process: Industry and Regulatory Initiatives: Centre for Medicines Research Workshop
Editat de C. Lumley, S.R. Walkeren Limba Engleză Paperback – 20 sep 2011
Preț: 1046.69 lei
Preț vechi: 1101.77 lei
-5%
Puncte Express: 1570
Carte tipărită la comandă
Livrare economică 03-17 septembrie
Livrare prin curier în România Termenul estimat este afișat lângă disponibilitate.
Transport gratuit pentru acest produs Plată online sau ramburs, în funcție de opțiunile comenzii.
Retur gratuit în 14 zile Comandă securizată și suport în română.
Specificații
ISBN-13: 9789401072977
ISBN-10: 9401072973
Pagini: 196
Ilustrații: XX, 172 p.
Dimensiuni: 155 x 235 x 10 mm
Greutate: 0.29 kg
Ediția:Softcover reprint of the original 1st ed. 1996
Editura: SPRINGER NETHERLANDS
Colecția Springer
Seria Centre for Medicines Research Workshop
Locul publicării:Dordrecht, Netherlands
ISBN-10: 9401072973
Pagini: 196
Ilustrații: XX, 172 p.
Dimensiuni: 155 x 235 x 10 mm
Greutate: 0.29 kg
Ediția:Softcover reprint of the original 1st ed. 1996
Editura: SPRINGER NETHERLANDS
Colecția Springer
Seria Centre for Medicines Research Workshop
Locul publicării:Dordrecht, Netherlands
Public țintă
ResearchCuprins
1 International regulatory review times.- 2 What determines speed of review: Need for the product, quality of the dossier or efficiency of regulatory authorities?.- 3 Company strategies to ensure a quick and efficient review: Abiotech company.- 4 Company strategies to ensure a quick and efficient review: A Japanese company.- 5 Company strategies to ensure a quick and efficient review: A transnational company.- 6 Conditional licensing: Advantages and disadvantages.- 7 Dialogue and interaction between regulators and sponsors: Formal, informal or none at all?.- 8 The use of electronic dossiers or CANDAs: Help or hindrance?.- 9 The exchange of assessment reports and training of assessors.- 10 The regulatory assessment report in the new European system.- 11 Industry expert reports: An aid to the reviewer?.- 12 The use of internal and external experts and advisory boards: The European experience.- 13 Highlights of the Pharmaceutical Research and Manufacturers Association proposal for FDA reform.- 14 Suggestions that might be considered for improving the review process.- 15 The ideal future regulatory system: An industry perspective.- 16 What strategies should be considered forimplementation by the end of the century? MHW perspective.- 17 What strategies should be considered for implementation by the end of the century? European perspective.- 18 What strategies should be considered for implementation by the end of the century? CBER vision.- Meeting participants.